Fulcrum Therapeutics ( (FULC) ) has released its Q4 earnings. Here is a breakdown of the information Fulcrum Therapeutics presented to its investors.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to treat genetically defined rare diseases, with a lead program targeting sickle cell disease (SCD).
In its latest earnings report, Fulcrum Therapeutics highlighted its progress in the Phase 1b PIONEER trial for its lead drug candidate, pociredir, aimed at treating SCD. The company ended 2024 with a solid cash position of $241 million, providing a financial runway into at least 2027.
Key financial metrics revealed a significant increase in collaboration revenue to $80 million for 2024, primarily due to an upfront payment from Sanofi, while research and development expenses decreased due to cost-sharing agreements. The company also reported a reduced net loss for the year, reflecting strategic cost management and a workforce reduction.
Looking ahead, Fulcrum Therapeutics remains focused on advancing its clinical trials for pociredir, with data from the 12 mg and 20 mg dose cohorts expected in 2025. The company is also progressing its program for inherited aplastic anemias and plans to submit an IND for Diamond-Blackfan anemia by the end of 2025.